Northwest Biotherapeutics (NWBO) EBIT (2010 - 2026)

Northwest Biotherapeutics' EBIT history runs 17 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• On a quarterly basis, EBIT rose 37.03% year-over-year to -$10.9 million in Q1 2026; TTM through Mar 2026 was -$53.5 million, a 21.41% increase from a year earlier, with the FY2025 full-year figure at -$59.9 million, up 9.91% from the prior year.
• EBIT improved to -$10.9 million in Q1 2026 per NWBO's latest filing, from -$13.5 million in the prior quarter.
• Across five years, EBIT topped out at -$10.9 million in Q1 2026 and bottomed at -$21.1 million in Q2 2022.
• The 5-year median for EBIT is -$14.8 million (2024), against an average of -$15.3 million.
• Biggest YoY gain for EBIT was 37.22% in 2022; the steepest drop was 70.27% in 2022.
• Year by year, EBIT stood at -$18.2 million in 2022, then advanced by 16.7% to -$15.1 million in 2023, then fell by 22.17% to -$18.5 million in 2024, then increased by 27.0% to -$13.5 million in 2025, then gained by 19.28% to -$10.9 million in 2026.
• Per Business Quant, the three latest NWBO EBIT figures stand at -$10.9 million (Q1 2026), -$13.5 million (Q4 2025), and -$14.3 million (Q3 2025).